Sr. Director, Elrexfio Marketing Team Lead

5 Every 24 seconds, someone in the world is diagnosed with blood cancer. Despite recent advances, there remain significant unmet needs for patients. With over a decade of experience in Hematology-Oncology at Pfizer, our impact is driven by our science. Our blood cancer medicines span our three core scientific modalities: Antibody-drug conjugates (ADCs), IO biologics including bispecific antibodies (BsAbs) and Small Molecules. There are three major blood cancer types, and Pfizer has treatments within each including Lymphoma, Myeloma, and Leukemia. Currently in the US, Pfizer has six hematologic medicines across its broad portfolio, bringing hope and relief to thousands of people suffering from blood cancers globally. Over the last decade, we've made strides in blood cancers, but our work in Hematology is far from finished. The Senior Director, Multiple Myeloma Team Lead role is a strong opportunity for an experienced, motivated and innovative leader with a track record of success in marketing new molecules within a highly competitive environment. This role will be responsible for the success of Elrexfio's early lifecycle go-to-market approach, including strategy and investments across all marketing verticals. This role will report into the VP, US Hematology Franchise Lead and will drive the success of Elrexfio in the US market, including multiple launches in new indications. Given the highly competitive market, success will rely on speed to market, robust clinical data, and establishing Pfizer leadership in multiple myeloma. This leader will be required to leverage their breadth and depth of US commercial marketing experience to lead a highly talented team of Hematology marketers and work closely within the Glocal construct to ensure we are executing upon an integrated strategy that maximizes our patient impact. ? Lead full P&L, LE's and financial obligations of the brand, with expected peak revenue following future indications at $4B+ Lead and oversee US Launch of Elrexfio in new disease states, including Double Class Exposed (DCE) And Newly Diagnosed (NDMM) ? Lead all marketing verticals and investments, including HCP, Patient, Account and Payer marketing, with accountability of $38M A&P investment decision-making ? Lead all Sr. Leadership reporting and progress, including but not limited to Quarterly Earnings Preparation, Quarterly Business Reviews (QBRs), Launch Readiness Briefings (TApply Job!